UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 18, 2010

 

 

MOLECULAR INSIGHT PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

 

 

 

 

Massachusetts   001-33284   04-0562086

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

160 Second Street, Cambridge, Massachusetts 02142

(Address of Principal Executive Offices, Including Zip Code)

(617) 492-5554

(Registrant’s Telephone Number, Including Area Code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement with Certain Officers.

(b) On October 18, 2010, Dr. Norman LaFrance, M.D., Senior Vice President and Chief Medical Officer, notified Molecular Insight Pharmaceuticals, Inc. (the “Company”) of his resignation from the Company, effective November 5, 2010.

 

Item 7.01. Regulation FD Disclosure.

On October 19, 2010, the Company issued a press release announcing Dr. LaFrance’s resignation. A copy of this press release is furnished with this Current Report on Form 8-K and attached hereto as Exhibit 99.1.

Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act.

 

Item 9.01. Financial Statements and Exhibits.

 

  (d) Exhibits. The following exhibit is furnished pursuant to Item 7.01:

 

  99.1     Press Release of Molecular Insight Pharmaceuticals, Inc., dated October 19, 2010.

 

2

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, hereunto duly authorized, on the 19 th day of October, 2010.

 

MOLECULAR INSIGHT PHARMACEUTICALS, INC.
By:  

/ S /    C HARLES H. A BDALIAN , J R .        

Name:   Charles H. Abdalian, Jr.
Title:   Chief Financial Officer

 

3

 

Exhibit Index to Current Report on Form 8-K

 

Exhibit

Number

      
99.1    Press Release of Molecular Insight Pharmaceuticals, Inc., dated October 19, 2010.

 

4

Molecular Insight Pharmaceuticals (MM) (NASDAQ:MIPI)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024 Click aqui para mais gráficos Molecular Insight Pharmaceuticals (MM).
Molecular Insight Pharmaceuticals (MM) (NASDAQ:MIPI)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024 Click aqui para mais gráficos Molecular Insight Pharmaceuticals (MM).